Premier Alternatives

BioIntelliSense

Denver, CO · Founded 2019 · Privately Held (backing)

Developer of a remote patient monitoring device designed to enhance healthcare delivery. BioIntelliSense is based in Denver, CO and was founded in 2019. Its last reported valuation was $1.2 billion in Dec 2022. It has raised $319 million across 4 recorded rounds; the latest was a $58.3 million later-stage round in Dec 2025.

Last reported valuation
$1.2B
Oct 2026
Priced at
—
Total raised
$318.6M
Last round
Later Stage VC
Dec 2025

BioIntelliSense key facts

as of Oct 2026
  • Developer of a remote patient monitoring device designed to enhance healthcare delivery.
  • BioIntelliSense is valued at approximately $1.2B as of Oct 2026 (last reported valuation).
  • It has raised $318.6M across 4 recorded rounds; the latest was Later Stage VC ($58.3M) in Dec 2025.
  • Notable investors include Chimera Capital, TLG Capital Management, Mary Tolan, Confluent, Dexcom Ventures — 18 tracked in total.
  • BioIntelliSense has filed 4 Form Ds with the SEC since 2020, most recently Dec 2025 ($58.1M sold to 4 investors).
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$1.2B

BioIntelliSense's last reported valuation, Dec 2022. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of BioIntelliSense with a free account
  • ·The complete investor list: 18 names
  • ·Watch BioIntelliSense: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

BioIntelliSense funding rounds

4 rounds
Dec 2025Later Stage VC$58.3MSEC filing▮
Apr 2021Early Stage VC$45.0MSEC filing▮
Aug 2020Early Stage VC$12.0MSEC filing▮
Dec 2018Early Stage VC$25.0MSEC filing▮
Full funding history →

BioIntelliSense valuation

BioIntelliSense's last reported valuation was $1.2 billion in Dec 2022. No priced round, secondary trade or fund mark has surfaced since.

How much has BioIntelliSense raised?

BioIntelliSense has raised $319 million in total; 4 of its rounds are on record, from 2018 on. The largest on record was a $58.3 million later-stage round in Dec 2025.

BioIntelliSense has filed 4 Form Ds with the SEC since 2020, most recently in Dec 2025 ($58.1 million sold to 4 investors).

BioIntelliSense investors

18 investors are on record for BioIntelliSense, including Chimera Capital, TLG Capital Management, Mary Tolan and Confluent. The later-stage round in Dec 2025 drew 14 investors.

About BioIntelliSense

Developer of a remote patient monitoring device designed to enhance healthcare delivery. The company's device provides continuous, passive monitoring of vital signs and biometrics through medical-grade wearable devices with actionable health insights and supporting early intervention, enabling healthcare providers to improve patient outcomes, streamline clinical workflows and reduce hospital readmissions.

Sector
Healthcare
HQ
Denver, CO, United States
Founded
2019
Employees
102
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.